Szabados Tamara, Makkos András, Ágg Bence, Benczik Bettina, Brenner Gábor G, Szabó Márta, Váradi Barnabás, Vörös Imre, Gömöri Kamilla, Varga Zoltán V, Görbe Anikó, Bencsik Péter, Ferdinandy Péter
Cardiovascular Research Group, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Pharmahungary Group, Szeged, Hungary.
Br J Pharmacol. 2025 Jan;182(2):432-450. doi: 10.1111/bph.17345. Epub 2024 Oct 29.
MicroRNA (miRNA) therapy is a promising approach to induce cardioprotection. We have previously identified cardiac microRNA-125b* (microRNA-125b-2-3p; miR-125b*) as a potential cardioprotective miRNA, termed ProtectomiR. We aimed to characterize the pharmacokinetics and pharmacodynamics, and the effect of miR-125b* mimic on infarct size using an in vivo mouse model.
To characterize the pharmacokinetics properties of miR-125b* mimic, a single injection of 10-μg miR-125b* mimic or its scramble miRNA control, or vehicle i.v. was given to C57BL/6 mice. MiR-125b* expression was measured from plasma, heart, kidney and liver samples. Effect of miR-125b* on area at risk and infarct size was assessed after 45-min coronary occlusion, followed by 24-h reperfusion; 10-μg miR-125b* mimic or 10-μg non-targeting miRNA mimic control or vehicle were administered via the right jugular vein at 10th mins of coronary occlusion. To assess molecular mechanism involved in cardioprotection, expression of mRNA targets of miR-125b* were measured from ventricular myocardium at 1, 2, 4, 8 or 24 h post-treatment using quantitative real time polymerase chain reaction.
MiR-125b* expression was markedly increased in plasma and myocardium 1 h, and in the liver 2h after treatment. Infarct size was significantly reduced after miR-125b* mimic treatment when compared to the vehicle. The expression of Ccna2, Eef2k and Cacnb2 target mRNAs was significantly reduced 8 h after injection of miR-125b* mimic.
This is the first demonstration of pharmacokinetic and molecular pharmacodynamic properties as well as the cardioprotective effect of miR-125b* mimic in vivo.
This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.
微小RNA(miRNA)疗法是一种诱导心脏保护的有前景的方法。我们之前已将心脏微小RNA-125b*(微小RNA-125b-2-3p;miR-125b*)鉴定为一种潜在的心脏保护miRNA,称为保护miR。我们旨在使用体内小鼠模型来表征其药代动力学和药效学,以及miR-125b*模拟物对梗死面积的影响。
为了表征miR-125b模拟物的药代动力学特性,向C57BL/6小鼠静脉内单次注射10μg miR-125b模拟物或其乱序miRNA对照或赋形剂。从血浆、心脏、肾脏和肝脏样本中测量miR-125b的表达。在冠状动脉闭塞45分钟后,然后再灌注24小时后,评估miR-125b对危险区域面积和梗死面积的影响;在冠状动脉闭塞第10分钟时,通过右颈静脉给予10μg miR-125b模拟物或10μg非靶向miRNA模拟物对照或赋形剂。为了评估心脏保护所涉及的分子机制,在治疗后1、2、4、8或24小时,使用定量实时聚合酶链反应从心室心肌中测量miR-125b的mRNA靶标的表达。
治疗后1小时血浆和心肌中以及2小时肝脏中miR-125b的表达显著增加。与赋形剂相比,miR-125b模拟物治疗后梗死面积显著减小。注射miR-125b*模拟物8小时后,Ccna2、Eef2k和Cacnb2靶mRNA的表达显著降低。
这是首次在体内证明miR-125b*模拟物的药代动力学和分子药效学特性以及心脏保护作用。
本文是主题为“非编码RNA疗法”的特刊的一部分。要查看本节中的其他文章,请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc。